Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Phase 2 Completed 32 enrolled SCRI Development Innovations, LLC Bristol-Myers Squibb · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective in the treatment of metastatic breast cancer

Timeline

Start: 2006-01
Primary completion: 2008-02
Completion: 2010-11

Publications

Results Yardley DA, McCleod M, Schreiber F, Murphy P, Patton J, Thompson DS, Shastry M, Rubin M, Melnik M, Burris HA, Hainsworth JD. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest. 2010 Nov;28(9):925-31. doi: 10.3109/07357907.2010.496755.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trastuzumab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Vinflunine	Small molecule	280 mg/m2	Intravenous
Subject	Vinflunine	Small molecule	320 mg/m2	Intravenous

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Summary

Timeline

Publications

Drugs

Indications